Expert Consensus on Microtransplant for Acute Myeloid Leukemia in Elderly Patients -Report From the International Microtransplant Interest Group

Recent studies have shown that microtransplant (MST) could improve outcome of patients with elderly acute myeloid leukemia (EAML). To further standardize the MST therapy and improve outcomes in EAML patients, based on analysis of the literature on MST, especially MST with EAML from January 1st, 2011 to November 30th, 2022, the International Microtransplant Interest Group provides recommendations and considerations for MST in the treatment of EAML. Four major issues related to MST for treating EAML were addressed: therapeutic principle of MST (1), candidates for MST (2), induction chemotherapy regimens (3), and post-remission therapy based on MST (4). Others included donor screening, infusion of donor cells, laboratory examinations, and complications of treatment

A Book-Influence-Evaluation Method Based on User Ratings of E-Commerce Platform

In online social networks, finding high-influence nodes is a crucial component of complex network research. A new book impact evaluation method based on user rating is proposed in this research for the social network created by the buying and selling behaviors on the e-commerce platform. It intends to rank the book nodes in accordance with customer feedback data following user purchases. The method calculates the influence score of a book by predicting its popularity based on user evaluations of the book. To verify the validity and accuracy of the method, the research analyzes a real review dataset from Amazon, a large e-commerce platform, and designs two comparison experiments with different time spans and compares them with five other web analytics metrics. The experimental findings show that the method is efficient and precise in evaluating the influence of book nodes

Dual-Channel Edge-Featured Graph Attention Networks for Aspect-Based Sentiment Analysis

The goal of aspect-based sentiment analysis (ABSA) is to identify the sentiment polarity of specific aspects in a context. Recently, graph neural networks have employed dependent tree syntactic information to assess the link between aspects and contextual words; nevertheless, most of this research has neglected phrases that are insensitive to syntactic analysis and the effect between various aspects in a sentence. In this paper, we propose a dual-channel edge-featured graph attention networks model (AS-EGAT), which builds an aspect syntactic graph by enhancing the contextual syntactic dependency representation of key aspect words and the mutual affective relationship between various aspects in the context and builds a semantic graph through the self-attention mechanism. We use the edge features as a significant factor to determine the weight coefficient of the attention mechanism to efficiently mine the edge features of the graph attention networks model (GAT). As a result, the model can connect important sentiment features of related aspects when dealing with aspects that lack obvious sentiment expressions, pay close attention to important word aspects when dealing with multiple-word aspects, and extract sentiment features from sentences that are not sensitive to syntactic dependency trees by looking at semantic features. Experimental results show that our proposed AS-EGAT model is superior to the current state-of-the-art baselines. Compared with the baseline models of LAP14, REST15, REST16, MAMS, T-shirt, and Television datasets, the accuracy of our AS-EGAT model increased by 0.76%, 0.29%, 0.05%, 0.15%, 0.22%, and 0.38%, respectively. The macro-f1 score increased by 1.16%, 1.16%, 1.23%, 0.37%, 0.53%, and 1.93% respectively

A Novel Strategy to Enhance the Photostability of InP/ZnSe/ZnS Quantum Dots with Zr Doping

Plentiful research of InP semiconductor quantum dots (QDs) has been launched over the past few decades for their excellent photoluminescence properties and environmentally friendly characteristics in various applications. However, InP QDs show inferior photostability because they are extremely sensitive to the ambient environment. In this study, we propose a novel method to enhance the photostability of InP/ZnSe/ZnS QDs by doping zirconium into the ZnS layer. We certify that Zr can be oxidized to Zr oxides, which can prevent the QDs from suffering oxidation during light irradiation. The InP/ZnSe/ZnS:Zr QDs maintained 78% of the original photoluminescence quantum yields without significant photodegradation under the irradiation of LED light (450 nm, 3.0 W power intensity) for 14 h, while conventional InP/ZnSe/ZnS QDs dramatically decreased to 29%

Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study

Recombinant human TPO (rhTPO) is effective for refractory/relapsed primary immune thrombocytopenia (ITP), but optimal dosing regimen remains elusive. In this multicenter, randomized, controlled trial, a total of 282 adult ITP patients (mean age 47.3 years; 82 men) with a platelet count ≤30 × 109/L or >30 × 109/L with active bleeding randomly received a once daily (QD) subcutaneous injection of 7500 U (n = 64) or 15000 U rhTPO for 14 injections, or 15000 U or 30000 U rhTPO once every other day (QOD) for 7 injections. The primary outcomes included change from baseline in platelet count and total response rate (TRR) on day 14. On day 14, the median increase of platelet count from baseline was the highest in the 15000-U QD group (167.5 × 109/L, interquartile range [IQR] 23.0–295.0 × 109/L), followed by the 30000-U QOD group (57.5 × 109/L, IQR 9.0–190.0 × 109/L) (ANCOVA P P = .266 with baseline count as a covariate). The TRR on day 14 was also the highest in the 15000-U QD group (63.2%), followed by the 30000-U QOD group (59.7%). The rate of grade 3 and above adverse events did not differ among the four groups. There were no new safety concerns. All 4 regimens are safe and well-tolerated. The 30000-U QOD regimen is practically indistinguishable in efficacy to the 15000-U QD regimen. What is the context?Relative thrombopoietin deficiency is implicated in primary immune thrombocytopenia (ITP), which is characterized by increased platelet destruction and impaired megakaryopoiesis.Patients who are innately unresponsive to or have relapsed after glucocorticoid treatment have limited treatment options.Recombinant human thrombopoietin (rhTPO) improves treatment response of primary ITP patients when added to high-dose dexamethasone. Relative thrombopoietin deficiency is implicated in primary immune thrombocytopenia (ITP), which is characterized by increased platelet destruction and impaired megakaryopoiesis. Patients who are innately unresponsive to or have relapsed after glucocorticoid treatment have limited treatment options. Recombinant human thrombopoietin (rhTPO) improves treatment response of primary ITP patients when added to high-dose dexamethasone. What is new?This trial sought to identify an optimal dosing regimen of rhTPO for patients who had failed or relapsed after glucocorticoid therapy.Of the 4 regimens, once daily 15000 U rhTPO for 14 injections yielded the greatest median increase in platelet count (167.5 × 109/L) from baseline and attained the highest total response rate on day 14 (63.2%).30000 U rhTPO once every other day for 7 injections was effective in rapidly increasing platelet counts in the first 7 days.All 4 regimens were safe and well-tolerated. This trial sought to identify an optimal dosing regimen of rhTPO for patients who had failed or relapsed after glucocorticoid therapy. Of the 4 regimens, once daily 15000 U rhTPO for 14 injections yielded the greatest median increase in platelet count (167.5 × 109/L) from baseline and attained the highest total response rate on day 14 (63.2%). 30000 U rhTPO once every other day for 7 injections was effective in rapidly increasing platelet counts in the first 7 days. All 4 regimens were safe and well-tolerated. What is the impact?The 30000 U rhTPO once every other day regimen may offer an effective and safe regimen with less frequent injections, but future trials with longer follow-up are needed. The 30000 U rhTPO once every other day regimen may offer an effective and safe regimen with less frequent injections, but future trials with longer follow-up are needed.</p